AbCellera Biologics Inc. (ABCL)

Market Cap	877.24M
Revenue (ttm)	32.96M
Net Income (ttm)	-175.80M
Shares Out	295.37M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,563,554
Open	2.950
Previous Close	2.940
Day's Range	2.920 - 2.999
52-Week Range	2.335 - 5.620
Beta	0.40
Analysts	Buy
Price Target	8.00 (+169.36%)
Earnings Date	Feb 18, 2025

About ABCL

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 586
• Stock Exchange: NASDAQ
• Ticker Symbol: ABCL
• Website: https://www.abcellera.com

Analyst Forecast

According to 3 analysts, the average rating for ABCL stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 169.36% from the latest price.

Price Target

$8.0

(169.36% upside)

Analyst Consensus: Buy